Status:
COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer
Lead Sponsor:
Italian Trial in Medical Oncology
Conditions:
Prostate Cancer
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
The purpose of this study is to use Sorafenib plus Docetaxel to evaluate pharmacodynamics (PD) in Patients with prostate cancer.
Detailed Description
Background Prostate cancer is the most common malignancy in men and the second leading cause of cancer death among males in the Western World. When tumors become refractory to androgen withdrawal ther...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients with metastatic hormone refractory prostate cancer
Exclusion
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2009
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT00619996
Start Date
March 1 2007
End Date
January 1 2009
Last Update
February 26 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dipartimento di Oncologia, dei Trapianti e delle Nuove Tecnologie in Medicina ... Indirizzo: via Roma, 55 - 56100 Pisa Tel. 050-2218690 - Fax. 050-2218685
Pisa, Pisa, Italy, 56100